Ranitidine: Nursing Drug Guide, NDMA Withdrawal & NCLEX Review
The defining ranitidine safety story is no longer only renal dose adjustment—it is NDMA impurity that led the FDA to request U.S. market withdrawal, while lingering Zantac orders, home supplies, and international stock still reach the bedside. When the drug is used where available, continuing full 150 mg twice-daily dosing with creatinine clearance below 50 mL/min risks CNS toxicity and warfarin INR drift that reconciliation and pharmacy review must catch before administration.
In April 2020 the U.S. FDA requested withdrawal of all prescription and OTC ranitidine because N-nitrosodimethylamine (NDMA)—a probable human carcinogen—can increase over time and with storage above room temperature. Do not administer withdrawn U.S. product; verify formulary status, recall lists, and home medications at admission. Where ranitidine remains available outside withdrawn markets, labeling warns that the drug is substantially renally excreted: when creatinine clearance is less than 50 mL/min, use 150 mg every 24 hours and monitor for rare but serious CNS adverse reactions (confusion, agitation, hallucinations) in elderly and renally impaired patients. Reconcile duplicate acid-suppression orders and screen warfarin and pH-dependent drugs before every dose.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before any ranitidine dose, confirm the product is not on a withdrawal or recall list and the order has been reconciled to an approved alternative when required. If ranitidine is still used, verify CrCl is at least 50 mL/min or the dose is reduced to 150 mg every 24 hours—full BID dosing in renal impairment can cause confusion and agitation in elderly patients. Flag warfarin and duplicate PPI plus H2 therapy on every pass.
Most common brand names
Ranitidine was widely known as Zantac (ZANTAC 150 and ZANTAC 300 tablets per historical DailyMed labeling). Generic ranitidine hydrochloride tablets, capsules, and syrup were marketed under many names before the FDA withdrawal request. Combination kits that bundled ranitidine with other agents also appeared on formularies—verify each component during medication reconciliation.
Because U.S. ranitidine products were requested for market withdrawal, many facilities now substitute famotidine, omeprazole, or other acid suppressants. Do not assume “Zantac” on a home list is still an acceptable inpatient order—confirm formulary status and prescriber intent.
Why we give it — Indications
Ranitidine is a histamine H2-receptor antagonist that decreases gastric acid secretion. Historical prescribing information approved it for acid-mediated upper GI conditions listed below. Symptomatic relief does not exclude gastric malignancy—persistent alarm symptoms require diagnostic follow-up per prescriber plan.
| Use | Detail |
|---|---|
| Active duodenal ulcer (short-term) | 150 mg twice daily or 300 mg once daily at bedtime; most patients heal within 4 weeks per ranitidine labeling |
| Active benign gastric ulcer | 150 mg twice daily; most heal within 6 weeks per labeling |
| GERD | 150 mg twice daily; symptomatic heartburn relief often within 24 hours per clinical trials cited in labeling |
| Erosive esophagitis | 150 mg four times daily for up to 12 weeks when endoscopically diagnosed per labeling |
| Peptic ulcer maintenance | 150 mg at bedtime after acute ulcer healing for duodenal or gastric ulcer maintenance per labeling |
| Pathological hypersecretory conditions | Starting 150 mg twice daily, individualized up to 6 g/day in severe disease per labeling—use extreme caution in renal impairment |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Ranitidine competitively and reversibly inhibits histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion. It is not an anticholinergic agent and does not lower serum calcium in hypercalcemic states per labeling. Because approximately 30% of an oral dose is excreted unchanged in urine with active tubular secretion, renal impairment prolongs half-life and raises exposure unless the dose is reduced—this pharmacokinetic pattern drives CNS toxicity risk when nurses miss CrCl review.
Dosing overview
Adult oral dosing depends on indication. Ranitidine labeling lists standard regimens for patients with normal renal function and a single renal-adjustment rule when creatinine clearance is less than 50 mL/min. Dosing must be verified against current prescribing information, prescriber order, renal/hepatic function, and local policy—especially where national regulators have withdrawn ranitidine products.
Hepatic adjustment: Minor clinically insignificant alterations in ranitidine half-life and clearance in compensated cirrhosis per labeling—caution in hepatic dysfunction is still advised. Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance and do not double doses.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset / peak | Peak levels 440–545 ng/mL at 2–3 hours after 150 mg oral dose; ~50% oral bioavailability per labeling | Symptom relief may begin within 24 hours for GERD but erosive disease needs longer assessment |
| Duration | Serum concentrations inhibit 50% of stimulated acid secretion for up to 12 hours after 150 mg per labeling | BID regimens cover daytime and nocturnal acid; missed doses matter for ulcer healing |
| Half-life | 2.5–3 hours in adults with normal renal function; ~4.8 hours IV in CrCl 25–35 mL/min | Accumulation develops over days when renal dose is not reduced—CNS symptoms may lag first dose |
| Excretion | ~30% unchanged in urine within 24 hours; active tubular secretion | Trend serum creatinine and calculated CrCl before continuing home ranitidine doses in hospital |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm formulary status—do not administer U.S. withdrawn or recalled ranitidine; verify NDC, lot, and institutional recall lists with pharmacy
- Match ordered dose to renal function: CrCl <50 mL/min requires 150 mg every 24 hours per labeling
- Review allergy history; reconcile home Zantac, OTC acid reducers, and duplicate PPI plus H2 blocker orders
- Screen for warfarin, oral midazolam/triazolam, glipizide, and pH-dependent HIV/oncology drugs
- Baseline mental status in elderly and CKD patients—document orientation before first dose when ranitidine is still permitted
Contraindications
- Known hypersensitivity to ranitidine or formulation components
- History of acute porphyria—ranitidine may precipitate acute porphyric attacks per labeling; avoid in these patients
- Withdrawn or recalled product—do not administer pending pharmacist and prescriber substitution to an approved alternative
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Warfarin | Reports of altered prothrombin time with concurrent ranitidine—narrow therapeutic index | Monitor INR and bleeding signs; notify pharmacist and prescriber when ranitidine starts or stops |
| Ketoconazole | Oral ketoconazole exposure reduced up to 95% when gastric pH maintained ≥6 with ranitidine in a study cited in labeling | Flag chart; follow azole prescribing information for timing relative to acid suppression |
| Midazolam / triazolam (oral) | Increased benzodiazepine exposure when gastric pH rises—up to ~65% increase for oral midazolam at ranitidine 150 mg BID per labeling | Monitor for excessive or prolonged sedation; verify route (IV midazolam interaction less pronounced) |
| Atazanavir, delavirdine, gefitinib | Reduced absorption when gastric pH increases per labeling cross-references | Verify HIV/oncology regimens with pharmacist before starting or continuing ranitidine |
| Procainamide (high-dose ranitidine) | High ranitidine doses may reduce renal clearance of procainamide and NAPA per labeling | Notify pharmacist if Zollinger-Ellison–level doses are ordered with procainamide |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet, capsule, or syrup per historical ranitidine labeling. Absorption is not significantly impaired by food or antacids, though high-potency antacid in fasting subjects has been reported to decrease absorption. Antacids may be given as needed for pain relief with active ulcer disease per labeling.
- Typical adult timing: 150 mg twice daily, 300 mg at bedtime, or four-times-daily regimens for erosive esophagitis depending on indication
- Swallow tablets whole when possible; follow pharmacy guidance for crushing or enteral-tube administration
- Store at 15–30 °C, protect from light and moisture per labeling—NDMA can increase with heat exposure per FDA withdrawal rationale
- Do not administer if pharmacy flags withdrawn, recalled, or expired product
A MAR that still says “Zantac 150 mg BID” may be a legacy order from before the FDA withdrawal request. Hold the dose, notify pharmacy, and confirm whether an approved substitute (for example famotidine or a PPI) is ordered before administration. When ranitidine remains permitted, a patient with CrCl 42 mL/min should receive 150 mg every 24 hours, not standard twice-daily dosing.
Expected therapeutic response
- Decrease in heartburn, regurgitation, or epigastric discomfort when used for reflux or ulcer symptoms—GERD trials cited in labeling note relief within about 24 hours for many patients
- Reduced need for PRN antacids when ulcer symptoms improve per clinical trial data in labeling
- Ulcer or erosive esophagitis healing confirmed by endoscopy or prescriber assessment—not evaluated at the bedside alone
- Stable mental status after dose initiation when renal function and withdrawal status are correct—new confusion suggests hold and reassessment
Red flags — Stop and act
Stop ranitidine and escalate when withdrawal status is uncertain, neurotoxicity, serious hypersensitivity, or bleeding despite therapy is suspected—especially in elderly patients and those with CKD on unadjusted doses.
- Withdrawn, recalled, or unidentified ranitidine product on the MAR—hold immediately and notify pharmacy
- New or worsening confusion, agitation, depression, or hallucinations—consider ranitidine accumulation in renal impairment per labeling
- Bleeding, melena, hematemesis, or dropping hemoglobin despite acid suppression—may signal ulcer complication
- Rising INR or bleeding signs with concurrent warfarin—labeling reports altered prothrombin time
- Rising creatinine or oliguria suggesting acute kidney injury—reassess renally cleared drugs before the next dose
- Severe rash, angioedema, bronchospasm, or anaphylaxis—discontinue and initiate emergency pathway per protocol
- Abdominal pain, dysphagia, or unintentional weight loss despite therapy—may signal gastric malignancy per labeling precaution
- Excessive sedation when oral midazolam or triazolam is co-administered—acid suppression increases benzodiazepine exposure per labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Headache, constipation, diarrhea, nausea/vomiting | Reported in clinical trials and postmarketing per labeling | Document and trend; evaluate persistent GI symptoms for alternate causes |
| CNS reactions (confusion, agitation, depression, hallucinations, dizziness, somnolence) | Rare; predominantly in severely ill elderly patients per labeling | Hold ranitidine; notify prescriber; verify renal dose; monitor mental status and fall risk |
| Cardiovascular (tachycardia, bradycardia, AV block, premature beats) | Rare reports with H2 blockers per labeling | Monitor vitals and symptoms; notify prescriber if symptomatic |
| Hepatitis, hepatocellular injury, jaundice | Occasional reports; usually reversible but deaths reported rarely | Discontinue immediately; monitor LFTs per prescriber |
| Hypersensitivity (anaphylaxis, angioedema, bronchospasm, rash) | Serious; potentially fatal | Discontinue immediately; emergency response per protocol |
| Hematologic (leukopenia, thrombocytopenia, agranulocytosis—rare) | Rare; often reversible per labeling | Monitor CBC when ordered; report fever or infection signs |
On a small screen, swipe or scroll sideways to see the full table.
Frequency terms are not uniformly quantified in ranitidine labeling; relationship to therapy was unclear for many postmarketing events per the adverse reactions section.
Overdose, toxicity, and antidote
Limited overdosage experience is described in ranitidine labeling. Acute ingestions up to 18 g orally have been associated with transient adverse effects similar to therapeutic doses. In renal impairment, standard doses may produce toxicity through accumulation rather than a single massive ingestion.
Management
- No specific antidote is listed in the reviewed prescribing information
- Treatment is symptomatic and supportive; remove unabsorbed material from the GI tract when appropriate
- Monitor mental status, vital signs, and gait or hypotension reported with overdose per labeling
- Hemodialysis reduces circulating ranitidine—schedule dosing around dialysis when applicable
Contact local poison control or medical toxicology services for over-exposure guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Ranitidine vs famotidine vs nizatidine—all H2 blockers with different availability and interaction profiles; verify correct drug after withdrawal-related substitutions
- Zantac vs Zantac OTC vs combination kits—confirm single-entity ranitidine versus bundled products on MAR
- 150 mg vs 300 mg tablets—strength mix-ups are common; read label and barcode at bedside
- Ranitidine vs PPIs—duplicate acid suppression after admission; reconcile home Zantac with inpatient PPI orders
- Legacy orders—automatic reordering of pre-2020 ranitidine templates without formulary check is a high-risk workflow failure
- Recalled lot numbers—pharmacy may flag NDMA-related recalls; nurses must not override without verification
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Withdrawal status | First question: is this product still on formulary and not recalled? If unsure, hold and ask pharmacy |
| Renal check | Before each dose when permitted: CrCl <50 mL/min → 150 mg q24h per labeling |
| Food / antacids | May give with food or antacids per labeling; still verify dose and withdrawal status |
| Mental status | Baseline orientation on start; screen elderly and CKD patients each shift for confusion |
| Warfarin pair | Flag combination; monitor INR and bleeding at each contact |
| Commonly missed | Home Zantac in belongings, unchanged BID dose after AKI, and PPI plus H2 overlap |
| Ask pharmacy when | Substitution after withdrawal, hemodialysis timing, tube administration, or pH-dependent HIV/oncology drugs |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Chronic kidney disease (CrCl <50 mL/min) | Mandatory dose reduction to 150 mg every 24 hours per labeling; half-life and exposure increase proportionally to renal impairment |
| Elderly patients | Substantially renally excreted; prolonged half-life in geriatric patients per labeling. Rare CNS adverse reactions reported predominantly in severely ill elderly patients. |
| Hemodialysis patients | Dialysis removes ranitidine; schedule doses at end of dialysis when possible per labeling |
| Patients on warfarin | Monitor INR closely—reports of altered prothrombin time per labeling |
| Acute porphyria history | Avoid ranitidine—labeling reports rare precipitation of acute porphyric attacks |
| Pregnancy | Pregnancy Category B per labeling; no adequate well-controlled human studies—use only if clearly needed |
| Lactation | Secreted in human milk per labeling—exercise caution when administered to nursing mothers |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Formulary and recall status at admission and when patients bring home medication
- Renal function—trend basic metabolic panel and calculated CrCl; reduce dose when CrCl falls below 50 mL/min
- Mental status—orientation, agitation, hallucinations, or new sedation in elderly and CKD patients
- INR and bleeding signs when warfarin is co-administered
- GI symptoms—heartburn relief, gastritis symptoms, stool pattern, and alarm features
- Sedation when oral benzodiazepines with pH-dependent absorption are co-administered
Document
- Pharmacy verification when ranitidine is held for withdrawal or substituted with another agent
- Dose, route, time, and renal function value used to verify the dose when administration proceeds
- Patient education on stopping home Zantac if product is withdrawn in their region
- Medication reconciliation notes when duplicate PPI/H2 therapy is stopped
Patient teaching
- Many regions have withdrawn ranitidine because of NDMA—do not use old Zantac bottles until your pharmacist or prescriber confirms safety and need
- If ranitidine is still prescribed, kidney disease may require once-daily dosing instead of twice-daily home regimens
- Report sudden confusion, agitation, unusual behavior, or extreme drowsiness immediately
- Tell your care team about warfarin, antifungals, and all OTC acid reducers
- Report black stools, vomiting blood, severe abdominal pain, or trouble swallowing—these are not normal reflux symptoms
- Seek urgent care for severe rash, facial swelling, or trouble breathing
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to ranitidine, acute porphyria history, or formulation intolerance
- Product is on FDA withdrawal list, recall, or formulary restriction—pending approved substitute
- Ordered dose exceeds renal adjustment (standard BID dosing when CrCl <50 mL/min without prescriber authorization)
- New confusion, agitation, hallucinations, or depression suspected to be drug-related—hold and evaluate for ranitidine CNS toxicity
- Rising INR or bleeding with concurrent warfarin after ranitidine starts or dose increases
- Duplicate PPI plus H2 blocker without documented indication, or unidentified home Zantac plus inpatient acid suppressant
- Creatinine rising acutely—reassess dose before giving scheduled ranitidine
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Ranitidine looks like a routine PRN acid reducer until a legacy Zantac order, NDMA withdrawal status, or renal dose error surfaces. The highest-yield nursing checks are formulary verification, CrCl-based dose reduction, warfarin INR monitoring, and stopping duplicate acid suppression.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and formulary / recall clearance before any ranitidine administration
- Verify renal-adjusted dose when CrCl <50 mL/min (150 mg q24h per labeling)
- Screen for duplicate PPI plus H2 blocker, home Zantac in belongings, and warfarin on the profile
- Baseline mental status in elderly and CKD patients when ranitidine remains permitted
2. High-alert and safety badge
Not a traditional high-alert medication—withdrawal & renal CNS focusRanitidine is not universally listed as a high-alert drug, but administering withdrawn product or unadjusted doses in renal impairment can cause serious harm. Treat NDMA withdrawal checks and renal dose verification with the same urgency as high-alert medication workflows.
3. Clinical workflow: hold and question rules
- If pharmacy flags withdrawn or recalled ranitidine on the MAR, hold and request substitution before any dose
- If CrCl is 42 mL/min and the MAR still shows ranitidine 150 mg BID, hold and request pharmacy verification
- If INR rises after ranitidine starts in a patient on warfarin, hold ranitidine and notify the team per protocol
4. Critical teach-back questions
- “Has your pharmacist told you to stop your old Zantac because of a safety recall?” (NDMA withdrawal may require switching to another acid reducer.)
- “What new confusion or mood changes should you report?” (Agitation, hallucinations, or unusual sleepiness—especially with kidney disease.)
5. Care coordination
Pharmacist: Withdrawal/recall verification, renal dose adjustment, warfarin interaction review, duplicate acid-suppression reconciliation, and hemodialysis timing
Prescriber / nephrology: Substitute therapy after withdrawal, worsening creatinine, persistent CNS symptoms despite dose hold, or bleeding with warfarin co-therapy
🧠 Quick mental checklist
- Is this ranitidine product still approved on our formulary—not withdrawn or recalled?
- What is the patient’s CrCl—and does the MAR show 150 mg q24h when CrCl <50?
- Any home Zantac or duplicate PPI plus H2 blocker on the profile?
- Is warfarin co-prescribed—and when was INR last checked?
- Any new confusion or agitation since the last ranitidine dose?
Ranitidine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for ranitidine using a tabbed case panel (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), INR/renal trend interpretation, renal-dose cloze, ordered response, and matrix urgency matching—recognise withdrawal and renal cues → analyse interactions → prioritise → act → evaluate outcomes when confusion and INR remain elevated after holding the legacy Zantac order.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Ranitidine (Zantac) 150 mg PO BID — carried forward from outpatient order; 0800 dose given yesterday
- Pantoprazole 40 mg PO daily — started hospital day 1 for GERD; both acid suppressants remain active
- Warfarin 5 mg PO daily — chronic atrial fibrillation anticoagulation
- 0900: ranitidine 150 mg due; pharmacy posted formulary alert: ranitidine not stocked (withdrawn)
- Admission BMP: creatinine 1.5 mg/dL; calculated CrCl ~40 mL/min; BUN 32 mg/dL
- Today: INR 3.8 (was 2.4 three days ago); hemoglobin 10.2 g/dL (down from 11.1)
- Potassium 4.6 mEq/L; magnesium 2.1 mg/dL
- BP 118/70, HR 82, RR 16, SpO₂ 97% on room air, temp 36.8 °C
- Reports mild epigastric burning; no hematemesis today
- Gums bleed easily when brushing—new finding this morning
- Fall precautions in place; Morse fall score 55
- 0700: Daughter brought full bottle of home Zantac 150 mg tablets in belongings
- 0830: Patient oriented ×2; intermittent agitation overnight calling for nurse repeatedly
- 1000: Pharmacy note: facility does not dispense ranitidine—substitute not yet ordered
- 1045: Nurse flagged duplicate pantoprazole plus ranitidine and rising INR on warfarin
Answer key & rationale
Frequently asked questions
Why did the FDA request withdrawal of ranitidine products?
In April 2020 the FDA requested manufacturers withdraw all prescription and OTC ranitidine because NDMA, a probable human carcinogen, can increase over time and with storage above room temperature. Ranitidine is not available for new or existing prescriptions or OTC use in the U.S. Nurses should reconcile lingering orders and home supplies with pharmacy and the prescriber.
When should ranitidine dose be reduced for renal impairment?
Ranitidine prescribing information recommends 150 mg every 24 hours when creatinine clearance is less than 50 mL/min. Frequency may be increased to every 12 hours with caution if clinically required. Hemodialysis reduces circulating ranitidine—time doses after dialysis when possible.
Why can ranitidine cause confusion in older adults with CKD?
Ranitidine is substantially renally excreted. Labeling reports rare reversible mental confusion, agitation, depression, and hallucinations—predominantly in severely ill elderly patients. Reduce the dose when CrCl is below 50 mL/min and monitor mental status.
When should a nurse hold ranitidine?
Hold for hypersensitivity, acute porphyria history, withdrawn or recalled product, supratherapeutic dosing for renal function, new CNS symptoms, rising INR with warfarin, duplicate PPI plus H2 therapy without intent, or acute creatinine rise before reassessment.
Does ranitidine interact with warfarin?
Ranitidine labeling reports altered prothrombin time among patients on concurrent warfarin therapy. Because warfarin has a narrow therapeutic index, monitor INR closely when ranitidine starts, stops, or doses change.
Is there an antidote for ranitidine overdose?
No specific antidote is listed in ranitidine overdosage labeling. Treatment is symptomatic and supportive; hemodialysis reduces circulating drug. Contact local poison control or toxicology services per facility protocol for over-exposure.
References
-
U.S. Food and Drug Administration. FDA requests removal of all ranitidine products (Zantac) from the market. Drug Safety and Availability; updated 2020.https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-all-ranitidine-products-zantac-market
-
U.S. National Library of Medicine. RANITIDINE tablets USP, 150 mg and 300 mg — Full prescribing information. DailyMed; revised February 2018.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9f506bf-21ef-4323-9ce8-e8a7b561c496
-
European Medicines Agency. EMA advises companies to recall ranitidine medicines. Press release; 2019.https://www.ema.europa.eu/en/news/ema-advises-companies-recall-ranitidine-medicines
-
National Institute for Health and Care Excellence (NICE). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184).https://www.nice.org.uk/guidance/cg184
-
U.S. National Library of Medicine. ZANTAC 150 and ZANTAC 300 (ranitidine hydrochloride) tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=08010bf7-1f61-48b3-e1b5-7cecb72ba863&type=display
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.